Post

MSF Access
@msfaccess.org

Publicly available information on pricing, licensing, supply, and post-trial access remains very limited despite repeated calls for transparency.

1 repost1 like

MSF Access
@msfaccess.org

“Funders, researchers and policymakers engaged in therapeutics' clinical trials must act now to include the right access conditions in a transparent way,” said Dr Monica Rull, MSF Access